Brazil Cough Hypersensitivity Syndrome Therapeutics Market Report 2022 to 2030

Brazil Cough Hypersensitivity Syndrome Therapeutics Market Analysis

$ 3999

The Brazil Cough Hypersensitivity Syndrome Therapeutics Market was valued at $203 Mn in 2022 and is predicted to grow at a CAGR of 6.9% from 2023 to 2030, to $345 Mn by 2030. The primary factors propelling this industry involve the surge in the prevalence of Cough Hypersensitivity Syndrome, high unmet medical needs, and growing healthcare expenditure. The industry is primarily dominated by players such as Sanofi, Pfizer, Teva, Novartis, Johnson & Johnson, and GSK among others.

ID: IN10BRPH316 CATEGORY: Pharmaceuticals GEOGRAPHY: Brazil AUTHOR: Riddhi Solanki

Buy Now

Brazil Cough Hypersensitivity Syndrome Therapeutics Market Analysis Executive Summary

The Brazil Cough Hypersensitivity Syndrome Therapeutics Market is at around $203 Mn in 2022 and is projected to reach $345 Mn in 2030, exhibiting a CAGR of 6.9% during the forecast period.

Cough Hypersensitivity Syndrome (CHS) is marked by an excessive response to stimuli, increasing cough reflex sensitivity, which shows signs of recurrent coughing caused by irritants such as dust, fragrances, or cold air. Common causes of CHS are respiratory infections, gastroesophageal reflux disease (GERD), and exposure to environmental toxins. Symptoms include a chronic cough associated with throat irritation or pain. CHS is effectively treated by addressing the underlying conditions and regulating the cough reflex. Antitussives, which block the cough reflex, and medications to treat underlying problems such as GERD are among the treatment options available. Pharmaceuticals such as GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim develop drugs for CHS treatment, offering a range of therapeutic options.

Conditions such as COPD and chronic cough that can cause CHS affect around 17% of the Brazilian population. The market is propelled by significant factors such as the upward trend in the prevalence of Cough Hypersensitivity Syndrome and subsequently its risk factors like smoking and pollution, high unmet medical needs, and growing healthcare expenditure. However, conditions such as limited treatment options, reimbursement challenges, and lack of awareness restrict the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Rising incidence of Cough Hypersensitivity Syndrome: Pre-existing conditions like COPD and chronic cough cause Cough Hypersensitivity Syndrome (CHS). Roughly 17% of the Brazilian population suffers from COPD which is steadily rising, leading to a huge patient pool requiring effective treatments.

Unmet medical need: There is no definite CHS treatment and available alternatives focus on symptom management. This gap in medical services allows for developing and accepting novel, effective drugs, promoting market growth.

Growing healthcare expenditure: The growing healthcare expenditure in Brazil including public and private sectors, leads to increased investments in the diagnosis and treatment of CHS. Government initiatives, such as the Global Alliance against Chronic Respiratory Diseases (GARD) Brazil, encourage early detection and treatment, expanding the patient pool and increasing market demand.

Market Restraints

Limited treatment options: Currently, the treatment relies on the off-label use of drugs designed for diseases such as asthma, GERD, or allergies which have adverse side effects and limited efficacy in long-term treatment which limits market expansion.

Reimbursement challenges: In Brazil, obtaining reimbursement for CHS therapy is difficult due to differences in healthcare plans. The use of off-label drugs presents financial difficulties for patients. CHS does not have a specific diagnostic code further limiting patient access and resulting in treatment non-compliance.

Lack of awareness: CHS is frequently misdiagnosed as other respiratory disorders like asthma or GERD, resulting in delayed treatment. Inadequate awareness of CHS symptoms among patients and healthcare providers delays early diagnosis and prompt treatment. The difficulty is aggravated by the scarcity of specialized pulmonologists and allergists, particularly in remote places, which complicates the diagnosing procedure.

Healthcare Policies and Regulatory Landscape

In Brazil, the main regulatory body overseeing drugs and pharmaceuticals is the National Health Surveillance Agency, known as Agência Nacional de Vigilância Sanitária (ANVISA). ANVISA operates under the Ministry of Health and plays a crucial role in ensuring the safety, efficacy, and quality of health-related products, including pharmaceuticals, medical devices, and food. The agency is responsible for regulating and approving the registration, manufacturing, marketing, and distribution of drugs in the country.

The process of obtaining licensure for drugs in Brazil involves a thorough evaluation by ANVISA. Applicants must submit comprehensive documentation, including data on product safety, efficacy, and quality, as well as evidence of compliance with Good Manufacturing Practices (GMP). ANVISA conducts a detailed review of the submitted information to assess whether the product meets the necessary standards. Once approved, the drug receives a registration number, allowing it to be legally marketed and distributed in Brazil.

The regulatory environment for new entrants is strict, necessitating adherence to ANVISA laws and undergoing thorough examinations to guarantee their goods satisfy the required criteria.

Competitive Landscape

Key Players

Pfizer
GlaxoSmithKline
Boehringer Ingelheim
AstraZeneca
Johnson & Johnson
Bayer
Novartis
Teva Pharmaceutical
Sanofi
Merck

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Brazil Cough Hypersensitivity Syndrome Therapeutics Market Segmentation

By Drug Class

Antitussive Agents
Corticosteroids
Short Acting Beta-2 Agonists
Anti-cholinergic
Antihistamines
Proton Pump Inhibitors
Others

By Route of Administration

Oral
Inhalation
Others

By End Users

Hospitals
Speciality Clinics
Homecare

By Distribution Channel

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.